	US 12,187,807 B2
	Antibody molecules to C5AR1 and uses thereof
Karthik Viswanathan, Waltham, MA (US); Brian Booth, Waltham, MA (US); Boopathy Ramakrishnan, Waltham, MA (US); Andrew Wollacott, Waltham, MA (US); Gregory Babcock, Waltham, MA (US); and Zachary Shriver, Waltham, MA (US)
Assigned to Visterra, Inc., Waltham, MA (US)
Filed by Visterra, Inc., Waltham, MA (US)
Filed on Aug. 18, 2023, as Appl. No. 18/452,173.
Application 18/452,173 is a division of application No. 17/147,842, filed on Jan. 13, 2021, granted, now 11,773,179.
Claims priority of provisional application 62/960,544, filed on Jan. 13, 2020.
Prior Publication US 2024/0076398 A1, Mar. 7, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01)]

4 Claims

1. An antibody molecule capable of binding to complement component 5a receptor 1 (C5aR1), comprising a VH and a VL, wherein the VH comprises:

i. an HCDR1 comprising an amino acid sequence of SEQ ID NO: 602;

ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO: 722; and

iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO: 842; and wherein the VL comprises:

i. an LCDR1 comprising an amino acid sequence of SEQ ID NO: 662,

ii. an LCDR2 comprising an amino acid sequence of SEQ ID NO: 782, and

iii. an LCDR3 comprising an amino acid sequence of SEQ ID NO: 902.